Predictors of clinical outcomes in patients given carvedilol for heart failure

被引:4
|
作者
Greenberg, Barry
Lottes, Sandra R.
Nelson, Jeanenne J.
Lukas, Mary Ann
Fowler, Michael B.
Massie, Barry M.
Abraham, William T.
Gilbert, Edward M.
Franciosa, Joseph A. [1 ]
机构
[1] Cornell Univ, Mt Sinai Sch Med, New York, NY USA
[2] Cornell Univ, Weill Med Coll, New York, NY USA
[3] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[4] GlaxoSmithKline, Philadelphia, PA USA
[5] GlaxoSmithKline, Res Triangle Pk, NC USA
[6] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[7] Vet Affairs Med Ctr, San Francisco, CA 94121 USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Ohio State Univ, Sch Med, Columbus, OH 43210 USA
[10] Univ Utah, Med Ctr, Salt Lake City, UT 84112 USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2006年 / 98卷 / 11期
关键词
D O I
10.1016/j.amjcard.2006.06.050
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Risk factors for outcomes in heart failure (HF) were derived from populations in clinical trials, at hospital discharge, or in localized geographic or socioeconomic strata before the widespread use of beta blockers. This study observed 4,280 patients in a community-based HF registry for 1 year after completing carvedilol titration. Independent risk factors for death, hospitalization for HF, or hospitalization for cardiovascular reasons other than HF were first identified by age-, gender-, and race-adjusted analyses, then by multivariate analysis adjusted simultaneously for all factors. Over this period, 7% of patients died, 11% were hospitalized for HF, 12% were hospitalized for other cardiovascular reasons, and 27% had >= 1 of these events. The most significant outcome predictors were New York Heart Association class III or IV, history of hospitalization for HF or other cardiovascular reasons, and angina pectoris, all associated with increased odds of having an adverse outcome (all p <= 0.001). The left ventricular ejection fraction was not a significant outcome predictor by multivariate analysis. The odds ratio for an adverse outcome was significantly reduced for patients with hypertensive or idiopathic causes of HF and for those whose physicians had graduated from medical school >= 24 years earlier compared with < 14 years,earlier (all p < 0.005). In conclusion, easily obtained historical information predicts clinical outcomes in patients with HF in the year after initiating carvedilol. In this unselected community population, these historical factors were better predictors of risk than the left ventricular ejection fraction. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1480 / 1484
页数:5
相关论文
共 50 条
  • [1] Statins and Response to Carvedilol Given to Patients with Chronic Heart Failure
    Nessler, Bohdan J.
    Golebiowska, Renata
    Gackowski, Andrzej
    Nessler, Jadwiga M.
    JOURNAL OF CARDIAC FAILURE, 2010, 16 (08) : S75 - S75
  • [2] Predictors of clinical outcomes in elderly patients with heart failure
    Manzano, Luis
    Babalis, Daphne
    Roughton, Michael
    Shibata, Marcelo
    Anker, Stefan D.
    Ghio, Stefano
    van Veldhuisen, Dirk J.
    Cohen-Solal, Alain
    Coats, Andrew J.
    Poole-Wilson, Philip P. A.
    Flather, Marcus D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (05) : 528 - 536
  • [3] Baseline predictors of tolerability to carvedilol in patients with chronic heart failure
    Krum, H
    Ninio, D
    MacDonald, P
    HEART, 2000, 84 (06) : 615 - 619
  • [4] Effects of carvedilol on quality of life and clinical outcomes in elderly patients with chronic heart failure
    Ganugrava, N.
    Jashi, I.
    Kobulia, B.
    Abashidze, R.
    Tabidze, G.
    CIRCULATION, 2008, 118 (12) : E317 - E317
  • [5] Effects of carvedilol on quality of life and clinical outcomes in elderly patients with chronic heart failure
    Nino, Ganugrava
    Irina, Jashi
    Bondo, Kobulia
    Rusudan, Abashidze
    CARDIOVASCULAR DRUGS AND THERAPY, 2007, 21 : S31 - S31
  • [6] Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol
    Nessler, Jadwiga
    Nessler, Bohdan
    Golebiowska-Wiatrak, Renata
    Palka, Ilona
    Gackowski, Andrzej
    Kitlinski, Mariusz
    Melander, Olle
    Fedorowski, Artur
    CARDIOLOGY JOURNAL, 2013, 20 (02) : 144 - 151
  • [7] Predictors of stable outcome in treating chronic heart failure patients with carvedilol
    Ho, WJ
    Tsay, PK
    Chu, PH
    Chang, CJ
    Kuo, CT
    Chen, WJ
    JAPANESE HEART JOURNAL, 2004, 45 (05): : 823 - 832
  • [8] Clinical and hemodynamic efficacy of carvedilol in patients with congestive heart failure
    Tereschenko, SN
    Demidova, IV
    Borisov, NE
    Moiseev, NS
    KARDIOLOGIYA, 1998, 38 (02) : 43 - 46
  • [9] Clinical trials of carvedilol in heart failure
    Tang W.H.W.
    Fowler M.B.
    Heart Failure Reviews, 1999, 4 (1) : 79 - 88
  • [10] Impact of different diuretics on clinical outcomes in heart failure patients receiving optimized treatment including carvedilol
    Borst, U
    Düsing, R
    Ziegler, J
    EUROPEAN HEART JOURNAL, 2003, 24 : 533 - 533